← Leaderboards
Monica Kraft
National Jewish Health
$36,612,836
Attributed
$76,734,843
Total exposure
31
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.9M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$106,960,500 · 35
By mechanism
OT2$30,962,150 · 2
U19$22,507,721 · 7
P01$13,085,295 · 7
U54$7,415,246 · 1
UL1$5,937,646 · 1
P50$5,463,474 · 2
Top collaborators
- Jennifer S Li13 shared
- James O. Mcnamara13 shared
- Leigh E Boulware10 shared
- Fernando D Martinez7 shared
- Eugene R Bleecker5 shared
- Donata Vercelli4 shared
- Scott Boitano3 shared
- Robert M Califf3 shared
Most similar at National Jewish Health
Same institution · by research overlap
- Everett Rand Sutherland$2,431,896
- Dennis R Voelker$17,845,148
- Richard J Martin$13,509,122
Others in their field
Top investigators on “Asthma”
- James E. Gern · University Of Wisconsin-Madison$159,588,264
- William W. Busse · University Of Wisconsin Madison$104,093,792
- Scott T Weiss · University Of California, San Diego$98,211,117
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$79,309,576
- Fernando D Martinez · University Of Arizona$66,357,737
- Wanda Phipatanakul · Boston Children'S Hospital$50,505,446
Research focus
AsthmaInflammationProgramsPhenotypeResearch PersonnelLungPulmonary Surfactant-Associated Protein AClinical ResearchCollaborationsImmune ResponseCytokineBaseNatural ImmunityResponseInterleukin-13SamplingInflammatoryHuman SubjectImmuneResourcesReceptorProductionParticipantSurfactant
Grant awards (136)
The Duke Senescent Cell Evaluations in Normal Tissues (SCENT) Mapping Center$2,450,312
U54 · FY2025 · AG
Innate Immunity and Viral Infection in Asthma$1,431,641
U19 · FY2025 · AI · contact PI
All of Us Research Program New York Consortium$500,000
OT2 · FY2025 · OD · contact PI
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection$487,374
U19 · FY2025 · AI · contact PI
Mount Sinai StARR Program - NHLBI$346,072
R38 · FY2025 · HL · contact PI
Administrative Core$149,506
U19 · FY2025 · AI · contact PI
All of Us Research Program New York Consortium$5,712,150
OT2 · FY2024 · OD · contact PI
The Duke Senescent Cell Evaluations in Normal Tissues (SCENT) Mapping Center$2,417,637
U54 · FY2024 · AG
Innate Immunity and Viral Infection in Asthma$1,431,641
U19 · FY2024 · AI · contact PI
All of Us Research Program New York Consortium$1,250,000
OT2 · FY2024 · OD · contact PI
Administrative Core$798,118
U19 · FY2024 · AI · contact PI
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection$287,587
U19 · FY2024 · AI · contact PI
Mount Sinai StARR Program - NHLBI$225,417
R38 · FY2024 · HL · contact PI
The Duke Senescent Cell Evaluations in Normal Tissues (SCENT) Mapping Center$2,547,297
U54 · FY2023 · AG
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma - Phase II$1,478,237
R42 · FY2023 · HL
Innate Immunity and Viral Infection in Asthma$1,431,641
U19 · FY2023 · AI · contact PI
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection$469,477
U19 · FY2023 · AI · contact PI
Administrative Core$205,428
U19 · FY2023 · AI · contact PI
Aspen Lung Conference: Asthma: Pathogenesis, Phenotypes, Therapies and Gaps$30,000
R13 · FY2023 · HL
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma - Phase II$1,955,594
R42 · FY2022 · HL
Innate Immunity and Viral Infection in Asthma$1,431,641
U19 · FY2022 · AI · contact PI
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection$450,752
U19 · FY2022 · AI · contact PI
Administrative Core$156,887
U19 · FY2022 · AI · contact PI
University of Arizona-Banner Health All of Us Research Program$11,500,000
OT2 · FY2021 · OD · contact PI
Innate Immunity and Viral Infection in Asthma$1,433,547
U19 · FY2021 · AI · contact PI
PrecISE Network: ADAPT (Advancing Severe Asthma Precision Therapy)$425,299
UG1 · FY2021 · HL · contact PI
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection$371,166
U19 · FY2021 · AI · contact PI
Administrative Core$146,789
U19 · FY2021 · AI · contact PI
University of Arizona-Banner Health All of Us Research Program$12,000,000
OT2 · FY2020 · OD · contact PI
Dysfunction of Innate Immunity in Asthma$1,395,363
U19 · FY2020 · AI · contact PI
The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)$561,279
U19 · FY2020 · AI · contact PI
Clinical Core$561,279
U19 · FY2020 · AI · contact PI
PrecISE Network: ADAPT (Advancing Severe Asthma Precision Therapy)$425,299
UG1 · FY2020 · HL · contact PI
Clinical Core$332,381
U19 · FY2020 · AI · contact PI
Regulation of Interleukin 13 by Surfactant Protein A in Asthma$282,948
U19 · FY2020 · AI · contact PI
Development of surfactant protein A-derived peptidomimetics for the treatment of asthma$214,912
R41 · FY2020 · HL · contact PI
Administrative Core$146,034
U19 · FY2020 · AI · contact PI
Dysfunction of Innate Immunity in Asthma$1,395,364
U19 · FY2019 · AI · contact PI
PrecISE Network: ADAPT (Advancing Severe Asthma Precision Therapy)$425,299
UG1 · FY2019 · HL · contact PI
Clinical Core$332,381
U19 · FY2019 · AI · contact PI
Regulation of Interleukin 13 by Surfactant Protein A in Asthma$265,874
U19 · FY2019 · AI · contact PI
Administrative Core$163,110
U19 · FY2019 · AI · contact PI
Dysfunction of Innate Immunity in Asthma$1,396,673
U19 · FY2018 · AI · contact PI
PrecISE Network: ADAPT (Advancing Severe Asthma Precision Therapy)$423,183
UG1 · FY2018 · HL · contact PI
Clinical Core$355,893
U19 · FY2018 · AI · contact PI
Regulation of Interleukin 13 by Surfactant Protein A in Asthma$263,854
U19 · FY2018 · AI · contact PI
Administrative Core$145,110
U19 · FY2018 · AI · contact PI
Dysfunction of Innate Immunity in Asthma$1,401,498
U19 · FY2017 · AI · contact PI
Duke CTSA (Composite)$1,319,247
KL2 · FY2017 · TR
Clinical Core$358,148
U19 · FY2017 · AI · contact PI
PrecISE Network: ADAPT (Advancing Severe Asthma Precision Therapy)$338,431
UG1 · FY2017 · HL · contact PI
Regulation of Interleukin 13 by Surfactant Protein A in Asthma$265,864
U19 · FY2017 · AI · contact PI
Administrative Core$143,486
U19 · FY2017 · AI · contact PI
Duke CTSA (Composite)$104,876
TL1 · FY2017 · TR
Dysfunction of Innate Immunity in Asthma$1,428,248
U19 · FY2016 · AI · contact PI
Duke CTSA (Composite)$1,319,247
KL2 · FY2016 · TR
Role of IL-13 and Hyaluronan (HA) in Ainway Remodeling in Asthma$384,650
P01 · FY2016 · HL · contact PI
Duke CTSA (Composite)$359,112
TL1 · FY2016 · TR
Clinical Core$267,204
U19 · FY2016 · AI · contact PI
Regulation of Interleukin 13 by Surfactant Protein A in Asthma$252,581
U19 · FY2016 · AI · contact PI
Administrative Core$109,954
U19 · FY2016 · AI · contact PI
Human Sample Core$93,097
P01 · FY2016 · HL · contact PI
Duke CTSA (Composite)$1,319,247
KL2 · FY2015 · TR
Role of IL-13 and Hyaluronan (HA) in Ainway Remodeling in Asthma$386,612
P01 · FY2015 · HL · contact PI
Arizona/Duke Clinical Center for AsthmaNet$174,854
U10 · FY2015 · HL
Human Sample Core$59,300
P01 · FY2015 · HL · contact PI
58th Annual Aspen Lung Conference$20,000
R13 · FY2015 · HL
Duke CTSA (Composite)$1
TL1 · FY2015 · TR
Duke CTSA (Composite)$879,498
KL2 · FY2014 · TR
HIV and Asthma in the Post- ART Era$729,181
R56 · FY2014 · HL
Arizona/Duke Clinical Center for AsthmaNet$501,452
U10 · FY2014 · HL
Duke CTSA (Composite)$449,290
UL1 · FY2014 · TR
Role of IL-13 and Hyaluronan (HA) in Ainway Remodeling in Asthma$392,343
P01 · FY2014 · HL · contact PI
Duke CTSA (Composite)$355,276
TL1 · FY2014 · TR
Duke CTSA (Composite)$71,747
UL1 · FY2014 · TR
Human Sample Core$59,000
P01 · FY2014 · HL · contact PI
Duke CTSA (Composite)$5,416,609
UL1 · FY2013 · TR
Arizona/Duke Clinical Center for AsthmaNet$862,742
U10 · FY2013 · HL
Role of IL-13 and Hyaluronan (HA) in Ainway Remodeling in Asthma$390,410
P01 · FY2013 · HL · contact PI
Duke CTSA (Composite)$355,276
TL1 · FY2013 · TR
Duke CTSA (Composite)$256,520
KL2 · FY2013 · TR
Surfactant Protein-A Regulation of Innate Immunityin Asthma$225,381
P01 · FY2013 · AI · contact PI
Administrative Core$142,466
P01 · FY2013 · AI · contact PI
Human Sample Core$57,313
P01 · FY2013 · HL · contact PI
Host Factors in Regulation of Inflammatory and Fibroproliferative Lung Disease$2,009,285
P01 · FY2012 · HL · contact PI
SP-A as an immune modulator$1,429,197
P01 · FY2012 · AI · contact PI
Arizona/Duke Clinical Center for AsthmaNet$862,566
U10 · FY2012 · HL
Human Sample Core$441,878
P01 · FY2012 · HL · contact PI
Role of IL-13 and Hyaluronan (HA) in Ainway Remodeling in Asthma$343,948
P01 · FY2012 · HL · contact PI
Surfactant Protein-A Regulation of Innate Immunityin Asthma$187,950
P01 · FY2012 · AI · contact PI
Administrative Core$101,459
P01 · FY2012 · AI · contact PI
SP-A as an immune modulator$1,692,145
P01 · FY2011 · AI · contact PI
Arizona/Duke Clinical Center for AsthmaNet$862,566
U10 · FY2011 · HL
Surfactant Protein-A Regulation of Innate Immunityin Asthma$254,543
P01 · FY2011 · AI · contact PI
Administrative Core$182,514
P01 · FY2011 · AI · contact PI
SP-A as an immune modulator$1,444,574
P01 · FY2010 · AI · contact PI
Arizona/Duke Clinical Center for AsthmaNet$862,566
U10 · FY2010 · HL
Airway Remondeling in Asthma: Modulation By IL-13$453,305
P50 · FY2010 · HL · contact PI
CLINICAL AND LABORATORY CORE$453,305
P50 · FY2010 · HL · contact PI
Platelet-Derived Growth Factor, Remodeling and Asthma$269,500
R01 · FY2010 · HL · contact PI
SP-A as an immune modulator$1,496,674
P01 · FY2009 · AI · contact PI
Arizona/Duke Clinical Center for AsthmaNet$536,491
U10 · FY2009 · HL
CLINICAL AND LABORATORY CORE$448,353
P50 · FY2009 · HL · contact PI
Airway Remondeling in Asthma: Modulation By IL-13$448,353
P50 · FY2009 · HL · contact PI
Platelet-Derived Growth Factor, Remodeling and Asthma$269,500
R01 · FY2009 · HL · contact PI
Airway Remondeling in Asthma: Modulation By IL-13$671,467
P50 · FY2008 · HL · contact PI
CLINICAL AND LABORATORY CORE$627,469
P50 · FY2008 · HL · contact PI
Mycoplasma-induced Airway Remodeling in Human Asthma$313,154
P01 · FY2008 · HL · contact PI
Platelet-Derived Growth Factor, Remodeling and Asthma$269,500
R01 · FY2008 · HL · contact PI
Airway Remondeling in Asthma: Modulation By IL-13$673,887
P50 · FY2007 · HL · contact PI
CLINICAL AND LABORATORY CORE$627,165
P50 · FY2007 · HL · contact PI
Mycoplasma-induced Airway Remodeling in Human Asthma$315,920
P01 · FY2007 · HL · contact PI
Platelet-Derived Growth Factor, Remodeling and Asthma$269,430
R01 · FY2007 · HL · contact PI
CLINICAL AND LABORATORY CORE$558,443
P50 · FY2006 · HL · contact PI
Airway Remondeling in Asthma: Modulation By IL-13$501,727
P50 · FY2006 · HL · contact PI
Mycoplasma-induced Airway Remodeling in Human Asthma$230,373
P01 · FY2006 · HL · contact PI
Mycoplasma-induced Airway Remodeling in Human Asthma$235,049
P01 · FY2005 · HL
NOCTURNAL ASTHMA: LINKING INFLAMMATION AND REMODELING$401,740
R01 · FY2004 · HL
Mycoplasma-induced Airway Remodeling in Human Asthma$216,060
P01 · FY2004 · HL
NOCTURNAL ASTHMA: LINKING INFLAMMATION AND REMODELING$85,294
R01 · FY2004 · HL
Eosinophil Influx Into the Lung In Nocturnal Asthma$1,463
M01 · FY2004 · RR
NOCTURNAL ASTHMA: LINKING INFLAMMATION AND REMODELING$307,600
R01 · FY2003 · HL
NOCTURNAL ASTHMA: LINKING INFLAMMATION AND REMODELING$307,600
R01 · FY2002 · HL
EOSINOPHIL INFLUX INTO THE LUNG IN NOCTURNAL ASTHMA$190,747
M01 · FY2002 · RR
COMPARISON OF CLINICAL BENEFIT, ANTIINFLAMMATORY EFFECT$190,747
M01 · FY2002 · RR
NOCTURNAL ASTHMA: LINKING INFLAMMATION AND REMODELING$269,150
R01 · FY2001 · HL
EOSINOPHIL INFLUX INTO THE LUNG IN NOCTURNAL ASTHMA$190,747
M01 · FY2001 · RR
COMPARISON OF CLINICAL BENEFIT, ANTIINFLAMMATORY EFFECT$190,747
M01 · FY2001 · RR
EOSINOPHIL INFLUX INTO THE LUNG IN NOCTURNAL ASTHMA$0
M01 · FY2001 · RR
COMPARISON OF CLINICAL BENEFIT, ANTIINFLAMMATORY EFFECT$0
M01 · FY2001 · RR
NOCTURNAL ASTHMA: LINKING INFLAMMATION AND REMODELING$230,700
R01 · FY2000 · HL
EOSINOPHIL INFLUX INTO THE LUNG IN NOCTURNAL ASTHMA$111,618
K08 · FY2000 · HL
COMPARISON OF CLINICAL BENEFIT, ANTIINFLAMMATORY EFFECT$32,212
M01 · FY2000 · RR
EOSINOPHIL INFLUX INTO THE LUNG IN NOCTURNAL ASTHMA$32,212
M01 · FY2000 · RR
COMPARISON OF CLINICAL BENEFIT, ANTIINFLAMMATORY EFFECT$0
M01 · FY2000 · RR
EOSINOPHIL INFLUX INTO THE LUNG IN NOCTURNAL ASTHMA$0
M01 · FY2000 · RR